Your browser doesn't support javascript.
Neutralizing antibody responses 300 days after SARS-CoV-2 infection and induction of high antibody titers after vaccination.
Urlaub, Doris; Wolfsdorff, Natalie; Hoffmann, Jan-Erik; Dorok, Stefanie; Hoffmann, Markus; Anft, Moritz; Pieris, Naomi; Günther, Patrick; Schaaf, Bernhard; Cassens, Uwe; Bröde, Peter; Claus, Maren; Picard, Lea K; Wingert, Sabine; Backes, Simone; Durak, Deniz; Babel, Nina; Pöhlmann, Stefan; Renken, Frank; Raunser, Stefan; Watzl, Carsten.
  • Urlaub D; Department for Immunology, Leibniz Research Centre for Working Environment and Human Factors (IfADo) at TU Dortmund, Dortmund, Germany.
  • Wolfsdorff N; Department for Immunology, Leibniz Research Centre for Working Environment and Human Factors (IfADo) at TU Dortmund, Dortmund, Germany.
  • Hoffmann JE; Protein Chemistry Facility, Max Planck Institute of Molecular Physiology, Dortmund, Germany.
  • Dorok S; Protein Chemistry Facility, Max Planck Institute of Molecular Physiology, Dortmund, Germany.
  • Hoffmann M; Infection Biology Unit, German Primate Center - Leibniz Institute for Primate Research, Göttingen, Germany.
  • Anft M; Faculty of Biology and Psychology, Georg-August-University Göttingen, Göttingen, Germany.
  • Pieris N; Center for Translational Medicine and Immune Diagnostics Laboratory, Marien Hospital Herne, University Hospital of the Ruhr-University Bochum, Herne, Germany.
  • Günther P; Department for Immunology, Leibniz Research Centre for Working Environment and Human Factors (IfADo) at TU Dortmund, Dortmund, Germany.
  • Schaaf B; Department of Structural Biochemistry, Max Planck Institute of Molecular Physiology, Dortmund, Germany.
  • Cassens U; Department of Respiratory Medicine and Infectious Diseases, Klinikum Dortmund, Dortmund, Germany.
  • Bröde P; Faculty of Health, University Witten/Herdecke, Herdecke, Germany.
  • Claus M; Institute for Transfusion Medicine, Laboratory Medicine and Medical Microbiology, Medical Center Dortmund, Dortmund, Germany.
  • Picard LK; Department for Immunology, Leibniz Research Centre for Working Environment and Human Factors (IfADo) at TU Dortmund, Dortmund, Germany.
  • Wingert S; Department for Immunology, Leibniz Research Centre for Working Environment and Human Factors (IfADo) at TU Dortmund, Dortmund, Germany.
  • Backes S; Department for Immunology, Leibniz Research Centre for Working Environment and Human Factors (IfADo) at TU Dortmund, Dortmund, Germany.
  • Durak D; Department for Immunology, Leibniz Research Centre for Working Environment and Human Factors (IfADo) at TU Dortmund, Dortmund, Germany.
  • Babel N; Institute for Virology and Immunobiology, University of Wuerzburg, Wuerzburg, Germany.
  • Pöhlmann S; Dortmund Health Department, Dortmund, Germany.
  • Renken F; Center for Translational Medicine and Immune Diagnostics Laboratory, Marien Hospital Herne, University Hospital of the Ruhr-University Bochum, Herne, Germany.
  • Raunser S; Infection Biology Unit, German Primate Center - Leibniz Institute for Primate Research, Göttingen, Germany.
  • Watzl C; Faculty of Biology and Psychology, Georg-August-University Göttingen, Göttingen, Germany.
Eur J Immunol ; 52(5): 810-815, 2022 05.
Article in English | MEDLINE | ID: covidwho-1729125
ABSTRACT
Neutralizing antibodies against SARS-CoV-2 are important to protect against infection and/or disease. Using an assay to detect antibodies directed against the receptor binding domain (RBD) of SARS-CoV-2 Spike, we identified individuals with SARS-CoV-2 infection after an outbreak at a local health institution. All but one COVID-19 patient developed detectable anti-RBD antibodies and 77% had virus neutralizing antibody titers of >125. Antibody levels declined slightly over time. However, we still detected virus neutralizing antibody titers in 64% of the COVID-19 patients at >300 days after infection, demonstrating durability of neutralizing antibody levels after infection. Importantly, full COVID-19 vaccination of these individuals resulted in higher antibody titers compared to fully vaccinated individuals in the absence of prior infection. These data demonstrate long-lived antibody-mediated immunity after SARS-CoV-2 infection, and a clear benefit of two vaccine doses for recovered individuals.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Eur J Immunol Year: 2022 Document Type: Article Affiliation country: Eji.202149758

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Eur J Immunol Year: 2022 Document Type: Article Affiliation country: Eji.202149758